Specify a stock or a cryptocurrency in the search bar to get a summary
Carmat
ALCARCarmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France. Address: 36, avenue de l'Europe, Vélizy-Villacoublay, France, 78140
Analytics
WallStreet Target Price
7.21 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALCAR
Dividend Analytics ALCAR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALCAR
Stock Valuation ALCAR
Financials ALCAR
Results | 2019 | Dynamics |